EP Patent

EP3878462A1 — Use of dnase to improve safety and efficacy of cancer radiotherapy

Assigned to CLS Therapeutics Ltd · Expires 2021-09-15 · 5y expired

What this patent protects

The invention relates to the use of a deoxyribonuclease (DNase) enzyme for prevention or amelioration of toxicity associated with various cytostatic and/or cytotoxic chemotherapeutic compounds and radiation therapy.

USPTO Abstract

The invention relates to the use of a deoxyribonuclease (DNase) enzyme for prevention or amelioration of toxicity associated with various cytostatic and/or cytotoxic chemotherapeutic compounds and radiation therapy.

Drugs covered by this patent

Patent Metadata

Patent number
EP3878462A1
Jurisdiction
EP
Classification
—
Expires
2021-09-15
Drug substance claim
No
Drug product claim
No
Assignee
CLS Therapeutics Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.